Drug Profile
TG 02 - Targovax
Alternative Names: TG02 - TargovaxLatest Information Update: 15 Jan 2021
Price :
$50
*
At a glance
- Originator Targovax
- Class Antineoplastics; Cancer vaccines; Peptide vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Helper-inducer T-lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 05 Jan 2021 Targovax grants an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics for clinical development and licensing of TG 02 in China, Hong Kong, Macau and Singapore
- 11 Mar 2020 Tagrovax announces intention to submit Investigational New Drug Application (IND) to National Medical Products Administration (NMPA) in China
- 11 Mar 2020 Tagrovax plans clinical trials in China and Singapore